ArticleJournal of advanced research2026
BMP9 alleviates iron accumulation-induced osteoporosis via the USP10/FOXO1/GPX4 axis.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Cell Type-Specific Ferroptosis Regulatory Networks in the Bone Microenvironment: Implications for the Pathogenesis and Treatment of Osteoporosis.Traffic (Copenhagen, Denmark) · 2026Review
- Naringenin ameliorates postmenopausal osteoporosis by inhibiting BMSC oxidative stress via the PI3K/AKT/NRF2 pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Reconstituted phospholipid membrane-coated FeBioactive materials · 2026Article
- Ferroptosis in musculoskeletal disorders: Emerging mechanisms and therapeutic opportunities (Review).International journal of molecular medicine · 2026Review
- FTMT-mediated suppression of mitophagy links iron accumulation to osteoporosis.Redox biology · 2026Article
- USP10 deubiquitinase: Physiological function, diseases and therapeutic target (Review).International journal of molecular medicine · 2026Review
- Dual immunosuppression mechanism induced by PTP1B in colorectal cancer: upregulation of PD-L1 by FOXO1/miR-34C/c-MYC axis and inhibition of the infiltration of CD8(+) T cell by downregulating of CXCL11.Journal of translational medicine · 2026Article
- QiangGuYin-containing serum improves osteogenic differentiation via regulating osteoclast-derived exosomal miR-27b-3p.Journal of molecular histology · 2026Article
- Review
- Propofol in combination with salvianolic acid A protect against lipopolysaccharide-induced cardiac dysfunction and ferroptosis through activating the SIRT1/FoxO1 signaling under diabetic condition.Annals of medicine · 2025Article
- p38 Regulates FoxO3a-Mediated SOD2 Expression to Prevent Cd-Induced Oxidative Stress in Neuronal Cells.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFerroptosis induced by iron accumulation can disrupt the physiological functions of bone marrow mesenchymal stem cells (BMSCs). BMP9 is an effective osteogenic factor. However, the role of BMP9 and its molecular mechanisms in osteoporosis induced by iron accumulation remain unclear.
objectivesThis study aims to explore the role and mechanism of BMP9 in alleviating iron accumulation induced osteoporosis.
methodsClinical samples were collected to analyze the relationship between iron accumulation and osteoporosis. The effect of BMP9 on lipid peroxidation levels in BMSCs under iron accumulation conditions was assessed using C11-BODIPY staining, MitoSOX staining, MDA and SOD activity measurement. The osteogenic capacity of BMP9 in BMSCs under iron accumulation conditions was evaluated by measuring ALP activity and calcium nodule formation. The mechanisms of BMP9 in regulating BMSCs under iron accumulation conditions were explored through experiments including cycloheximide treatment, RT-PCR, Western blot, GST pull-down, ChIP, and CO-IP.
resultsIt was observed in human samples that serum ferritin levels were negatively correlated with the bone mineral density of the lumbar spine and femoral neck. Meanwhile, ferroptosis is considered a key factor affecting bone health. Further research indicated that BMP9 could inhibit ferroptosis in cells and animal models with iron accumulation, while also improving oxidative stress and osteogenic capacity. In-depth investigation of its mechanism reveals that BMP9 promotes the expression of USP10, which removes the K48-linked ubiquitin chains on FOXO1, inhibiting its excessive ubiquitination in the cytoplasm. This stabilization allows FOXO1 to accumulate in the cytoplasm and eventually re-enter the nucleus. This process activated the expression of the key inhibitor of cell death, GPX4, enhancing the cell's antioxidant response, reducing ferroptosis-induced damage to BMSCs, and promoting their osteogenic differentiation.
conclusionThis study reveals that BMP9 inhibits ferroptosis through the USP10/FOXO1/GPX4 axis, providing a new therapeutic strategy for osteoporosis caused by iron accumulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.